Quadrant Capital Group LLC lifted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 71.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 146 shares of the medical research company’s stock after purchasing an additional 61 shares during the quarter. Quadrant Capital Group LLC’s holdings in Bio-Rad Laboratories were worth $61,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. WASHINGTON TRUST Co grew its stake in Bio-Rad Laboratories by 62.5% in the 4th quarter. WASHINGTON TRUST Co now owns 78 shares of the medical research company’s stock valued at $33,000 after buying an additional 30 shares during the last quarter. CI Investments Inc. grew its stake in Bio-Rad Laboratories by 50.0% in the 4th quarter. CI Investments Inc. now owns 84 shares of the medical research company’s stock valued at $35,000 after buying an additional 28 shares during the last quarter. AIA Group Ltd boosted its holdings in Bio-Rad Laboratories by 203.1% in the 4th quarter. AIA Group Ltd now owns 97 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 65 shares during the period. Romano Brothers AND Company bought a new stake in Bio-Rad Laboratories in the 4th quarter valued at $43,000. Finally, Atlas Capital Advisors LLC bought a new stake in Bio-Rad Laboratories in the 2nd quarter valued at $50,000. Institutional investors and hedge funds own 64.35% of the company’s stock.
Analysts Set New Price Targets
A number of analysts have weighed in on BIO shares. StockNews.com started coverage on shares of Bio-Rad Laboratories in a report on Thursday, May 18th. They issued a “buy” rating for the company. Credit Suisse Group increased their price target on shares of Bio-Rad Laboratories from $640.00 to $680.00 and gave the company an “outperform” rating in a report on Friday, February 17th. TheStreet raised shares of Bio-Rad Laboratories from a “d+” rating to a “c” rating in a report on Thursday, February 16th. Finally, Royal Bank of Canada increased their price target on shares of Bio-Rad Laboratories from $571.00 to $579.00 and gave the company an “outperform” rating in a report on Friday, February 17th. Four research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $653.00.
Bio-Rad Laboratories Price Performance
Bio-Rad Laboratories (NYSE:BIO – Get Rating) last released its quarterly earnings data on Thursday, May 4th. The medical research company reported $3.34 EPS for the quarter, topping analysts’ consensus estimates of $3.24 by $0.10. The company had revenue of $676.80 million during the quarter, compared to the consensus estimate of $689.28 million. Bio-Rad Laboratories had a negative net margin of 7.01% and a positive return on equity of 4.10%. The firm’s revenue for the quarter was down 3.3% compared to the same quarter last year. During the same period last year, the firm earned $4.94 EPS. As a group, equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 14.12 earnings per share for the current fiscal year.
Bio-Rad Laboratories Profile
Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.
Read More
- Get a free copy of the StockNews.com research report on Bio-Rad Laboratories (BIO)
- Shopify Soars 6% On Logistics Sale; EPS Forecast To Grow 715%
- Gevo’s Cash Flow, Small Cap Buying Back Shares
- Tesla: How and Why It Gets To $300
- Is American Airlines a Good Stock to Buy?
- High Dividend REITs: Are They an Ideal Way to Diversify?
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
